Profile data is unavailable for this security.
About the company
TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.
- Revenue in USD (TTM)24.74m
- Net income in USD-57.21m
- Incorporated2020
- Employees112.00
- LocationTriSalus Life Sciences Inc6272 W. 91st Ave.WESTMINSTER 80031United StatesUSA
- Phone+1 (415) 336-8917
- Fax+1 (302) 636-5454
- Websitehttps://trisaluslifesci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corp | 0.00 | -40.68m | 115.61m | 25.00 | -- | 3.74 | -- | -- | -1.23 | -1.23 | 0.00 | 0.8406 | 0.00 | -- | -- | 0.00 | -65.48 | -51.63 | -80.82 | -59.00 | -- | -- | -- | -- | -- | -21.59 | 0.4409 | -- | -- | -- | -5.11 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 116.43m | 140.00 | -- | 38.91 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -137.29m | 117.83m | 143.00 | -- | 0.5012 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| X4 Pharmaceuticals Inc | 563.00k | 17.63m | 118.98m | 93.00 | 8.24 | 1.26 | 6.59 | 211.33 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 119.82m | 246.00 | -- | -- | -- | 0.3889 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Cardiff Oncology Inc | 665.00k | -40.88m | 120.10m | 31.00 | -- | 2.25 | -- | 180.60 | -0.9142 | -0.9142 | 0.0149 | 1.15 | 0.0081 | -- | 2.17 | 21,451.61 | -49.98 | -31.24 | -57.60 | -33.56 | -- | -- | -6,143.91 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Nuvectis Pharma Inc | 0.00 | -21.10m | 120.31m | 13.00 | -- | 9.65 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 121.74m | 102.00 | -- | 1.72 | -- | 1,022.98 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 122.52m | 112.00 | -- | -- | -- | 4.95 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 123.30m | 64.00 | -- | 1.37 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Puma Biotechnology Inc | 219.14m | 8.72m | 125.07m | 185.00 | 13.93 | 2.55 | 6.16 | 0.5707 | 0.183 | 0.183 | 4.56 | 1.00 | 1.08 | 7.07 | 7.38 | 1,184,557.00 | 4.30 | -12.21 | 7.24 | -20.53 | 73.08 | 78.78 | 3.98 | -11.79 | 1.23 | 1.99 | 0.6474 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Actuate Therapeutics Inc | 0.00 | -27.77m | 127.28m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 128.76m | 8.00 | -- | 2.58 | -- | 13.34 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 129.55m | 159.00 | -- | 0.5552 | -- | 76.12 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Citius Oncology Inc | 0.00 | 1.93m | 129.77m | -- | 7.52 | 0.2626 | 67.12 | -- | 0.242 | 0.242 | 0.00 | 6.93 | 0.00 | -- | -- | -- | 3.25 | -- | 3.35 | -- | -- | -- | -- | -- | -- | -- | 0.036 | -- | -- | -- | 535.30 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -129.85m | 130.41m | 128.00 | -- | 0.5482 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Data as of Sep 23 2024. Currency figures normalised to TriSalus Life Sciences Inc's reporting currency: US Dollar USD
3.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Duquesne Family Office LLCas of 31 Mar 2024 | 315.96k | 1.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 162.02k | 0.60% |
| Geode Capital Management LLCas of 30 Jun 2024 | 137.89k | 0.51% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 54.48k | 0.20% |
| Connecticut Wealth Management LLCas of 31 Mar 2024 | 44.61k | 0.16% |
| Wolverine Asset Management LLCas of 30 Jun 2024 | 43.48k | 0.16% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 35.77k | 0.13% |
| Laird Norton Wetherby Wealth Management LLCas of 31 Mar 2024 | 34.95k | 0.13% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 28.42k | 0.11% |
| Anson Capital, Inc.as of 30 Jun 2024 | 24.42k | 0.09% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
